MARIZYME, INC.
MRZM evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $40K
- Lead Asset:
- duragraft (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for MRZM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$40K
Cash Runway
—
Lead Asset
duragraft (BLA Filed)
Next Catalyst
—
Tracking 3 pipeline candidates for MARIZYME, INC..
Run MARIZYME, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MARIZYME, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is MARIZYME, INC.'s lead drug candidate?
MARIZYME, INC.'s most advanced tracked candidate is duragraft (BLA Filed) for Cardiac bypass, peripheral bypass, and other vascular surgeries.
Who is the CEO of MARIZYME, INC.?
Mr. David L. Barthel M.B.A. is the chief executive officer of MARIZYME, INC. (MRZM).
Where is MARIZYME, INC. headquartered?
MARIZYME, INC. (MRZM) is headquartered in Jupiter, FL, United States.
What therapeutic areas does MARIZYME, INC. focus on?
MARIZYME, INC. develops therapies across Cardiovascular, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.